UBS has maintained its Buy rating and HK$52.6 target price on Tigermed (03347).
Tigermed has announced that it will participate, through its wholly owned subsidiary Hong Kong Tigermed, in the privatization and business spin-off of Frontage (01521).
UBS believes that if the transaction is completed as planned, Tigermed could acquire the non-target businesses in mainland China and approximately RMB 1.81 billion in cash, and would be entitled to receive additional consideration payments from Charles River Laboratories. The transaction could help Tigermed divest non-core businesses and focus on clinical CRO services.
The report noted that the cancellation price for each Frontage share is HK$2.37, representing a premium of about 59.1% over the closing price of HK$1.49 on November 9, and a premium of 107.2% over the average share price over the past 360 days, equivalent to a price-to-earnings ratio of about 91.6 times for Frontage in 2025.
After the privatization is completed, Tigermed plans to acquire the non-target businesses in mainland China at a preliminary valuation of about US$205.5 million; the target businesses such as bioanalysis and drug metabolism and pharmacokinetics (DMPK) will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; and Frontage founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.
Comments